Aldeyra Therapeutics, Inc Expected to Earn FY2019 Earnings of ($2.19) Per Share (NASDAQ:ALDX)

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Cantor Fitzgerald issued their FY2019 earnings estimates for shares of Aldeyra Therapeutics in a research note issued on Thursday, October 17th. Cantor Fitzgerald analyst L. Chen anticipates that the biotechnology company will earn ($2.19) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $33.00 target price on the stock. Cantor Fitzgerald also issued estimates for Aldeyra Therapeutics’ FY2020 earnings at ($2.06) EPS.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.02.

A number of other equities analysts have also recently commented on the stock. Zacks Investment Research raised shares of Aldeyra Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 14th. ValuEngine raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $24.19.

Shares of Aldeyra Therapeutics stock opened at $5.96 on Monday. The firm’s fifty day simple moving average is $5.49 and its 200-day simple moving average is $6.29. The stock has a market capitalization of $161.07 million, a price-to-earnings ratio of -3.33 and a beta of 0.86. Aldeyra Therapeutics has a 12 month low of $4.31 and a 12 month high of $12.79.

A number of large investors have recently bought and sold shares of ALDX. Meeder Asset Management Inc. boosted its stake in shares of Aldeyra Therapeutics by 989.5% during the 3rd quarter. Meeder Asset Management Inc. now owns 10,448 shares of the biotechnology company’s stock valued at $54,000 after buying an additional 9,489 shares during the last quarter. D. E. Shaw & Co. Inc. purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $67,000. Cubist Systematic Strategies LLC purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $30,000. Point72 Asset Management L.P. purchased a new position in shares of Aldeyra Therapeutics during the 2nd quarter valued at approximately $1,950,000. Finally, Algert Global LLC boosted its stake in shares of Aldeyra Therapeutics by 28.6% during the 2nd quarter. Algert Global LLC now owns 29,840 shares of the biotechnology company’s stock valued at $179,000 after buying an additional 6,631 shares during the last quarter. Hedge funds and other institutional investors own 61.26% of the company’s stock.

In other news, Director Richard Douglas acquired 20,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $100,000.00. Following the transaction, the director now directly owns 70,000 shares in the company, valued at approximately $350,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Todd C. Brady acquired 14,288 shares of the stock in a transaction that occurred on Wednesday, September 18th. The stock was purchased at an average price of $5.91 per share, for a total transaction of $84,442.08. Following the completion of the transaction, the chief executive officer now owns 614,826 shares in the company, valued at $3,633,621.66. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 83,907 shares of company stock worth $456,912. 13.50% of the stock is currently owned by insiders.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Further Reading: Momentum Indicators

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit